Topic:

R&D

Latest Headlines

Latest Headlines

Approvals aren't enough; Big Pharma R&D restructuring will continue

Here's a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they were really, really bad at drug development.

A new era of immuno-oncology has arrived

After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, a new class of cancer treatments has finally made its way onto the market, opening up what's expected to become a multibillion-dollar industry.

The top 5 trends for biotech in 2015

Billions of dollars in new biotech investments are being made, R&D is being globalized more than ever before and new technologies and drug classes are moving fast through the clinic. FierceBiotech assesses what we believe are the 5 top trends to watch in the year ahead.

Gelatin-based nanoparticles enter brain to treat stroke in crucial time window

South Korean researchers at the University of Illinois Urbana-Champaign have developed a delivery technique that uses bits of gelatin to encapsulate drugs and carry them to the brain without surgery. The method shows promise for stroke patients, extending the window during which treatment can be effective.

Cerulean's RNA-based cancer candidate debuts in humans, enters clinical testing stage

Cerulean Pharma announced last week that the first patient has received its Phase I/IIa cancer candidate, CRLX301, delivered using its RNA-based Dynamic Tumor Targeting Platform.

Study: Devices for obstructive sleep apnea could improve symptoms of depression

As med tech companies home in on innovative devices to treat obstructive sleep apnea, a new review shows that using a nightly device to treat the disorder could also lessen symptoms of depression.

Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact

Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.

Roche makes diagnostics headway with Bina Technologies acquisition

Roche is decking the halls with diagnostics acquisitions and Bina Technologies is the company's latest target. 

UPDATED: NIH launches crowdsourcing challenge to commercialize its neurological medical devices

The National Institutes of Health is launching The Neuro Startup Challenge, a crowdsourcing competition featuring 72 teams from 80 hospitals and universities, with a goal of commercializing 16 of its neuroscience inventions, including enhancements to MRI machines.

New deer vaccine against mad-cow-like disease may help people too

A team led by scientists at New York University's Langone Medical Center announced on Sunday that they have successfully vaccinated five deer against chronic wasting disease--an illness related to the human brain disorder Creutzfeldt-Jakob disease.